Our Pipeline

Advancing transformational therapies for rare and life-threatening diseases.

Quetzal Therapeutics  is pioneering a new paradigm in the treatment of rare hematologic malignancies and rare diseases.

Our lead candidate, QTX-2101, targets APL with a novel approach to improve outcomes.

The Phase III clinical trial was initiated in December 2025, with registration-enabling activities underway.

Leveraging proprietary delivery systems and optimized formulations, we’re expanding our portfolio with additional programs in development—advancing a pipeline built to address unmet clinical needs.

Preclinical

Phase 1

Phase 2

Phase 3

Approved

QTX-2101 – APL → Phase III ongoing

Phase 3

QTX-2102 – Infectious Disease → Preclinical

Preclinical

Active Pipeline Expansion

In addition to QTX-2101, we are actively pursuing clinical programs with the potential to reshape treatment paradigms across oncology and rare disease spaces.

Expanded Access Policy (EAP)

Quetzal Therapeutics’ investigational therapy QTX-2101 is currently available only through participation in clinical trials.

Quetzal Therapeutics does not currently offer Expanded Access. If Expanded Access programs become available in the future, requests must be submitted by the patient’s treating physician and will be evaluated on a case-by-case basis.

For questions regarding potential future Expanded Access opportunities, please contact:
[email protected]

View Full Expanded Access Policy